AbbVie - 3 things to know about the company
In an age of AI and tech, while investors chase the next big thing, some sectors like the pharmaceutical industry have been neglected.
Let's make the learning process easy by just focusing on 3 points of a pharmaceutical company today - $AbbVie(ABBV.US$
1. Business model
AbbVie is a pharmaceutical company dedicated to the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies.
It is the sixth-largest biomedical company by revenue.
The company's primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection.
Apart from Humira, it also has drugs in other medical fields, such as immunology, oncology, neuroscience, aesthetics and eye care.
2. Patent and trademark is important in the pharmaceutical industry
Whenever a new drug is discovered, pharmaceutical companies will file for a patent. A patent provides a drug company to sell the drug exclusively without risking being copied for a period of time - usually 20 years.
So whatever groundbreaking drug has been developed by AbbVie, will usually be granted a patent.
3. Financial brief
Over the last 3 years, AbbVie has registered consecutive growth in its top line, operating earnings, and also its net earnings.
Earnings per share have also increased for the last 3 years.
AbbVie does look promising. What do you think?
DISCLAIMER
The information available in this article/report/analysis is for sharing and education purposes only. This is neither a recommendation to purchase or sell any of the shares, securities or other instruments mentioned; nor can it be treated as professional advice to buy, sell or take a position in any shares, securities or other instruments. If you need specific investment advice, please consult the relevant professional investment advice and/or for study or research only.
The information available in this article/report/analysis is for sharing and education purposes only. This is neither a recommendation to purchase or sell any of the shares, securities or other instruments mentioned; nor can it be treated as professional advice to buy, sell or take a position in any shares, securities or other instruments. If you need specific investment advice, please consult the relevant professional investment advice and/or for study or research only.
No warranty is made with respect to the accuracy, adequacy, reliability, suitability, applicability, or completeness of the information contained. The author disclaims any reward or responsibility for any gains or losses arising from the direct and indirect use & application of any contents of the article/report/written material
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Co-founder, chief editor and analyst of mykayaplus.com
6717Followers
13Following
7487Visitors
Follow
noglyph : $AbbVie (ABBV.US)$ has yielded a high approval rating from the Food and Drug Administration (FDA). The company's impressive efficacy has contributed to its success in the pharmaceutical industry. In sight of the acclaimed approvals for IMBRUVICA®, QULIPTA®, and RINVOQ® (2023).